Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Current Atherosclerosis Reports|April 18, 2008
PPARgamma agonists and coronary atherosclerosisMelanie S Sulistio, Adrienne Zion, Nandish Thukral, et al.
Cardiovascular Endocrinology & Metabolism|November 23, 2020
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case modelMouhamed Nashawi, Omar Sheikh, Mahnoor Mir, et al.
Heart Failure Reviews|June 26, 2020
Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fractionMouhamed Nashawi, Omar Sheikh, Ayman Battisha, et al.
The American Journal of Medicine|January 4, 2011
Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapiesRobert Chilton, Jamison Wyatt, Shailesh Nandish, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 22, 2016
Cardiac Manifestations of Congenital Generalized LipodystrophyVani P Sanon, Yehuda Handelsman, Son V Pham, et al.
Heart Failure Reviews|November 10, 2020
Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitorsMouhamed Nashawi, Omar Sheikh, Ayman Battisha, et al.
World Journal of Cardiology|January 24, 2022
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapyMouhamed Nashawi, Mahmoud S Ahmed, Toka Amin, et al.
Vascular Health and Risk Management|November 21, 2012
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersElaine Chiquette, Peter P Toth, Gilbert Ramirez, et al.
Diabetes Care|May 22, 2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME StudyMuhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, et al.
Current Cardiology Reviews|October 29, 2019
Withdrawal Notice: Management of Right Atrial Thrombus. Where is the Evidence? : A Narrative ReviewOmar Sheikh, Deven Gulick, Evan Saenger, et al.
Pageof 6